---
document_datetime: 2026-01-26 15:12:27
document_pages: 2
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/tovanor-breezhaler-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: tovanor-breezhaler-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 1.3020646
conversion_datetime: 2026-01-29 12:07:12.452425
docling_version:
  docling-serve: 1.11.0
  docling-jobkit: 1.9.0
  docling: 2.70.0
  docling-core: 2.61.0
  docling-ibm-models: 3.11.0
  docling-parse: 4.7.3
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Tovanor Breezhaler

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number   | Scope                              | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| Variation type IB /  | C.I HUMAN AND VETERINARY MEDICINAL | 06/08/2025                          |                                             | SmPC and PL                      |           |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000280394                     | PRODUCTS - C.I.z Implementation of QRD template - Accepted C.I.z. - to update section 6.1 of the SmPC and section 6 of the Package Leaflet to add to the list of excipients the complete components of capsule shell and printing ink, under a separate heading 'Capsule Shell'.                                                                                                                                                                                                                |            |     |
|---------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|
| Variation type IA / EMA/VR/0000272066 | A. ADMINISTRATIVE CHANGES - A.7 Deletion of manufacturing sites for an active substance, intermediate or finished product, packaging site, manufacturer responsible for batch release, site where batch control takes place, or supplier of a starting material, reagent or excipient (when mentioned in the dossier)* - Accepted B.II.b.5 Change to in-process tests or limits applied during the manufacture of the finished product - B.II.b.5.a Tightening of in- process limits - Accepted | 21/05/2025 | N/A |